ArticleInternational journal of general medicine2025
Serum FGF23 and DPP4 Levels as Biomarkers for Coronary Artery Disease Severity in Type 2 Diabetic Patients with Coronary Heart Disease.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate the relationship between serum fibroblast growth factor 23 (FGF23) and dipeptidyl peptidase 4 (DPP4) levels, and the severity and prognosis of coronary artery disease (CAD) in patients with type 2 diabetes mellitus (T2DM) and coronary heart disease (CHD). Methods: A total of 113 patients with both T2DM and CHD (T2DM+CHD group) and 74 patients with T2DM without CHD (T2DM-only group) who underwent coronary angiography between January 2021 and June 2023 were enrolled. Based on Gensini scores, the T2DM+CHD group was further divided into three subgroups: mild (n=38), moderate (n=46), and severe (n=29) lesions. Serum levels of FGF23 and DPP4 were determined using enzyme-linked immunosorbent assay (ELISA). Correlation analysis and logistic regression were conducted to assess the association between biomarker levels and both disease severity and prognosis. Receiver operating characteristic (ROC) curve analysis was used to evaluate the predictive value of these biomarkers. Results: Serum levels of FGF23 and DPP4 were significantly higher in the T2DM+CHD group than in the T2DM-only group (P<0.05), and increased progressively with the severity of CAD (P<0.05). A positive correlation was observed between the levels of these biomarkers and CAD severity (r=0.714 for FGF23; r=0.437 for DPP4; P<0.05). Patients with poor prognosis exhibited increased left atrial diameter (LAD) and biomarker levels, along with reduced left ventricular ejection fraction (LVEF) (P<0.05). Multivariate analysis identified increased LAD, moderate-to-severe CAD, and elevated levels of FGF23/DPP4 as independent risk factors for poor prognosis, while higher LVEF served as a protective factor (P<0.05). Moreover, a combined predictive model using both FGF23 and DPP4 demonstrated superior diagnostic performance (AUC=0.921; P<0.05) compared to the use of each biomarker individually. Conclusion: Elevated serum levels of FGF23 and DPP4 are significantly associated with both the severity and poor prognosis of CAD in patients with T2DM and CHD. These findings suggest that FGF23 and DPP4 may serve as valuable biomarkers for risk stratification and clinical decision-making in this patient population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.